Relationship between intradermal tumor suppression and tumor immunity.
Intradermal (id) injection of three tumor-immune stimulant mixtures (LSTRA-BCG, 13762A-BCG, CaD2-Corynebacterium parvum) was superior to the sc site for suppression of tumor growth: Suppression of LSTRA-BCG mixtures was even less efficient after an ip or iv injectiouppression at all four sites. In the LSTRA-BCG model, the id site was not uniquely favorable for either the afferent or efferent limb of the immune response; the other sites produced equally effectiveimmunization or rejection of tumor challenge. We concluded that local suppression of tumor cell-immune stimulant mixtures was frequently more effective in the skin than at other sites, that local tumor suppression did not depend primarily on tumor immunity, and that afferent and efferent tumor immunity were equally efficient by the four routes tested.
D000230:Adenocarcinoma / Q000276:immunology / Q000628:therapy; D000818:Animals; D001500:BCG Vaccine; D005260:Female; D006084:Graft Rejection; D007167:Immunotherapy; D007271:Injections, Intradermal; D007942:Leukemia, Experimental / Q000276:immunology / Q000628:therapy; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000276:immunology / Q000628:therapy; D051379:Mice; D008807:Mice, Inbred BALB C; D008811:Mice, Inbred DBA; D009163:Mycobacterium bovis / Q000276:immunology*; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000628:therapy*; D011425:Propionibacterium acnes / Q000276:immunology*; D051381:Rats; D011916:Rats, Inbred F344; D014185:Transplantation, Isogeneic
D001500:BCG Vaccine